To determine the incidence, severity, and preventability of and risk factors for medication-related harm (MRH) in community-dwelling older adults after hospital discharge. DESIGN: Systematic review. SETTING: A search of Medline, EMBASE, CINAHL, and the Cochrane Library was undertaken without time restrictions. PARTICIPANTS: Older adults (average age 65) participating in observational studies investigating postdischarge adverse drug reactions (ADRs) or adverse drug events (ADEs) within a defined follow-up period. MEASUREMENTS: One author screened abstracts of all articles to exclude obviously irrelevant articles. Two authors independently screened the remaining articles for inclusion. Two authors independently extracted data, including study characteristics, MRH incidence, and risk factors; a third reviewer critically appraised and verified the data. Disagreements were resolved through discussion. RESULTS: From 584 potentially relevant articles, 8 studies met our inclusion criteria: 5 North American and 3 European. Most of the included studies were of moderate quality. There was a wide range in MRH incidence, from 0.4% to 51.2% of participants, and 35% to 59% of MRH was preventable. MRH incidence within 30 days after discharge ranged from 167 to 500 events per 1,000 individuals discharged (17-51% of individuals). There is substantial methodological heterogeneity across multiple domains of the studies, including ADR and ADE definitions, characteristics of recruited populations, follow-up duration after discharge, and data collection.
C
utting severe, avoidable medication-related harm (MRH) in half over the next 5 years is a World Health Organization (WHO) global patient safety challenge 1 . MRH is often described in terms of adverse drug reactions (ADRs; noxious, unintended reactions caused by a medicine at appropriate dosage) or adverse drug events (ADEs; which include ADRs and injuries related to medicine use at inappropriate dosages (medical error)) [2] [3] [4] [5] [6] [7] . In this article, ADRs and ADEs are combined and called MRH, in accordance with recent WHO terminology 1 . Older adults (65) are a particularly high-risk population for MRH because of polypharmacy 8 and agerelated pharmacokinetic and pharmacodynamics changes. 9 Approximately 10% of hospital admissions of older adults are attributable to MRH 10 , and the incidence of MRH is increasing in Europe and the United States [11] [12] [13] [14] ; between 2005/06 and 2013/14, the rate of U.S. emergency department visits for MRH almost doubled, from 5.2 to 9.7 visits per 1,000 older adults. Excess healthcare costs in the United States due to preventable MRH to a community-dwelling older adult has been estimated at $2,000. 15 Reducing MRH during transitions of care is a priority area in the WHO's global challenge 16 . Patients and caregivers describe the transition period around hospital discharge as a unique situation that presents a high risk for the occurrence of MRH [17] [18] [19] . During this period, confusion and inaccuracies in medicines management compound the deconditioning the occurs from hospitalization, alongside ongoing recovery from illness 20 . Medication discrepancies affect up to half of older adults around hospital discharge, 21 and administrative difficulties with receiving medicines and poor education regarding medication use can compound this situation 22 . Coordination between secondary care, primary care, patients, and caregivers after hospital discharge is commonly inadequate. Based on 4 studies from the United States and Australia, a recent systematic review found that primary care physicians never receive 5% to 38% of discharge summaries 23 . The quality of information communicated is also problematic. For instance, the same review found that 40% of discharge summaries did not provide diagnostic test results, 75% provided no information on pending tests, 22% lacked information on discharge medications, and 58% did not communicate follow-up plans.
A review of medication problems that older adults experienced around hospital discharge was conducted almost a decade ago 24 . Fourteen studies of medication problems in community and care home settings were identified, including medication discrepancies, education, nonadherence, drug interactions, and MRH. The authors could not estimate the magnitude of the problem because of study heterogeneity. In the meantime, despite no systematic quantification of the problem, there have been numerous interventional studies to reduce MRH in the postdischarge period 25, 26 . In view of this, we conducted a systematic review to investigate the epidemiology of MRH, in contrast to all medication problems that may or may not cause harm. Our aim was to determine the incidence, severity, preventability, and risk factors, associated with MRH in community-dwelling older adults after discharge.
METHODS
We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance (Supplementary  Table S1 ) in conjunction with the Joanna Briggs Institute methodological guidance for systematic reviews of observational epidemiological studies 27 . Our primary objective was to provide a synthesis of the epidemiological data on MRH in community-dwelling older adults after hospital discharge.
Search strategy
Two authors (NP, TR) conducted an electronic search of Medline, EMBASE, CINAHL, and the Cochrane Library from their inceptions to June 2016 without restrictions. We reran this search in June 2017 looking for any new studies. The search strategy was designed in Medline (using the Healthcare Databases Advanced Search from the National Institute of Health and Care Excellence) using a combination of key words and Medical Subject Headings (Supplementary Table S2 ). We subsequently adapted this search strategy for EMBASE and CINAHL.
Key concepts in the search strategy were adverse drug reaction, elderly, and hospital discharge. For each of these concepts, synonyms, related terms and controlled vocabulary terms were selected and combined using Boolean and proximity operators and truncation to ensure that alternative forms were retrieved. In addition, reference lists of relevant articles were scanned to identify any articles not found in the electronic search. We also consulted the studies in a review published in 2010 on a similar theme 24 , conducted forward citation searches on this prior review and on studies that we identified for inclusion, and successfully corresponded with investigators of 4 included studies to ensure that we did not miss any articles.
Selection criteria
We considered all published observational studies that evaluated MRH (ADR or ADE) in community-dwelling older adults (average age 65) within a defined follow-up period after hospital discharge. We included studies in which the incidence or prevalence of MRH was reported or could be calculated. Given that our objective was to establish the extent of MRH in the general older population discharged from the hospital, we had the following exclusion criteria: studies investigating only rehospitalized individuals; studies investigating only individuals with a specific disease or condition or harms of one particular medicine; and studies of institutionalized individuals.
Outcomes
Our primary outcome of interest was incidence of MRH after discharge. Secondary outcomes included the proportion of serious events, preventable events, and associated risk factors.
Study selection
One author (NP) screened titles and abstracts of identified articles to exclude obviously irrelevant articles (n5338). Two authors (NP, AP) independently screened the remaining papers (n5215), excluding those identified as reviews, interventional studies, conference proceedings, research letters and protocol papers, articles related to a specific medicine or condition, and articles not investigating the posthospital discharge period. The same two authors independently reviewed full-text articles of potentially eligible titles and abstracts and selected articles according to the inclusion criteria. A third author (KA) then reviewed these studies to confirm their eligibility for inclusion. Any disagreement was resolved through discussion.
Data extraction
Two reviewers (NP, AP) independently extracted data onto a standard data collection form (Table S3) , which a third reviewer (KA) verified. We extracted data from included articles on study year and country; study design; discharge setting; duration of follow-up; methods used for data collection and causality assessment; and ADE and ADR incidence or prevalence, severity, and preventability and associated risk factors.
Quality assessment
Two authors (NP, AP) independently assessed the quality of included studies using the Joanna Briggs Institute critical appraisal tool for prevalence studies 27 . The 9 domains in this tool address sampling bias (target population, sampling, sample size, description of participants and setting), coverage bias (coverage of identified sample), measurement bias (methods to identify outcome, reliability in outcome measurement, appropriate statistical analysis), and nonresponse bias (response rate). Any disagreements that arose were resolved through discussion. A risk-of-bias figure was completed for included studies using RevMan Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Data synthesis
We report the incidence proportions of MRH stated in the included studies. In studies in which this was not clearly stated, we calculated the incidence proportion from the available data (number of persons that developed MRH/ total population at risk). If the number of events within the population was stated, we also calculated the incidence of events per 1,000 discharges. We have not reported incidence rates (in which follow-up time is incorporated into the denominator) because this would be misleading, given that the risk of MRH after hospital discharge is not constant over time. Data were extracted on the medicine classes commonly implicated in MRH. If this was reported in an alternative format (e.g., mixture of medicine classes and specific medicines themselves), we categorized the medicines using the WHO Anatomical Therapeutics Coding system 28 .
RESULTS

Study Selection
We identified 584 individual records from our search strategy, out of which we read 31 articles in full because they were deemed relevant based on their title and abstract. From this, we excluded 24 articles because they did not meet all the inclusion criteria, and 1 additional study was identified from a reference list of an article. Therefore, 8 observational studies met our inclusion criteria ( Figure 1 ).
Study Characteristics
Study characteristics are outlined in Tables 1 and 2 . Five studies were conducted in North America 29-33 and 3 in Europe (Netherlands 34 , Croatia, 35 France 36 ). All identified studies were cohort studies (prospective, n55; retrospective, n52), with the exception of 1 prospective Records screened aŌer duplicates removed (n = 584)
Full-text arƟcles assessed for eligibility (n = 31) Full-text arƟcles excluded due to focus on medicaƟon issues other than MRH i.e. polypharmacy (n=3), inappropriate prescribing (n=3), medicaƟon discrepancies (n=3), paƟent knowledge (n=1), risk factors (n=1); average parƟcipant age <65 (n=6); hospital-based study (n=4); alternaƟve analysis of included arƟcle (n=1); not specific to post-discharge period (n=2) Studies included for systemaƟc synthesis (n = 8)
Records excluded due to irrelevance of Ɵtle and abstract (n=338); review paper, intervenƟonal study, conference proceedings, research leƩers, protocol paper (n=79); arƟcle related to specific medicine or condiƟon (n=67); study not invesƟgaƟng period post-hospital discharge (n=69) Figure 1 . Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram for included studies. population-based study 36 . The number of participants included in the studies ranged from 209 to 7,540, and the mean age of participants ranged from 67.7 to 80.0.
Participant recruitment and follow-up
The recruitment setting varied between studies, with most studies recruiting from general medical wards, although some specified inclusion of individuals from surgical wards 30 and all wards 36 . Most studies excluded individuals discharged to a nursing home, those with a terminal illness, and those admitted to psychiatric units, although 1 exclusively recruited individuals discharged to receive nursing care at home 31 . Three studies excluded individuals with dementia; one excluded all individuals with dementia 35 , 1 excluded those with severe dementia 30 , and 1 excluded those with dementia and no home caregiver 31 . Objective criteria for the diagnosis and severity of dementia were not reported.
The period of posthospital discharge follow-up was 1 month in 5 studies 29, 31, 33, 35, 36 ; the shortest follow-up was 2 weeks 34 , and the longest was 1 year 30 . Half of the studies recruited individuals from more than 1 hospital 30, 33, 34, 36 . A nationwide study of postdischarge ADRs from France recruited individuals whose general practitioner (GP) referred them to the hospital for any cause and then followed up only the subset of those that reconsulted their GP within 30 days of discharge 36 .
Definition of MRH
Definitions of MRH varied between studies, with 2 studies not reporting a definition 29, 31 . Two studies used a WHO definition of ADRs 35, 36 , and 1 used a modification of this to include harm from therapy discontinuation 36 . Another study classified a range of medication problems under ADRs, including "unsafe drug for patient, allergic reaction, contraindication present, incorrect administration, clinically relevant drug interaction, undesirable effect" 33 . Two studies reporting ADEs had a similar definition 29, 32 , but 1 of these included harms from nonadherence. 32 
Data collection and MRH causality assessment
Data collection was primarily through medical chart reviews 32, 33 and in some cases participant interview; participants were interviewed over the telephone 29, 30 or inperson 31, 34, 36 , and in 1 study, the interview was combined with a physical examination 35 . A range of health professionals, including communitybased pharmacy technicians 34 , clinical pharmacists, 32 GPs, 36 and physicians with expertise in clinical pharmacology, 35 collected data. Only some studies reported use of a tool to attribute causality to a medicine for a particular harm, including the validated Naranjo algorithm 30, 31, 35 and an algorithm that French experts in pharmacovigilance designed 37 .
Methodological Quality
The results of our critical appraisal of the included studies can be seen in Supplementary Figure S1 . Overall, the literature base was of moderate quality. Our assessment found that, in 5 of 8 studies, the sample frame (recruited cohorts to investigate the target population) was associated with a high risk of bias 30, 31, 33, 34, 36 . Quality indices that we found to have low risk of bias included sample size, sampling method, and methods used to identify MRH. 
Incidence of MRH
The incidence proportion of MRH ranged from 0.4% within 30 days of discharge in a French study of individuals with ADRs presenting to primary care after discharge 36 to 51.2% over a 2-week postdischarge period in a Dutch study reporting 'side-effects' of medicines 34 (Table 3 ). The incidence of MRH events ranged from 4.0 per 1,000 individuals over 30 days to 615.1 per 1,000 over 1 year of follow-up 30 . Follow-up in most studies (n55, 62.5%) was 30 days. 29, 31, 33, 36, 37 MRH incidence within 30 days after discharge ranged from 167 to 500 events per 1,000 participants (17-51% of discharged participants), 26, 29, 31, 33 excluding the very low MRH incidence reported in one study in which only participants consulting their GP were followed. 36 The substantial methodological variation between studies precludes reliable meta-analysis of MRH incidence 27 .
Severity, preventability and risk factors
Severity of MRH was determined in 4 studies. 30, 32, 36, 37 Two studies used the same criteria to define serious MRH; 36,37 death, life-threatening, hospitalization, or disability. The proportion of total MRH judged serious ranged from 6.9% 35 to 60% 37 ( Table 3) . Preventability of MRH was reported in 4 studies with variable definitions and ranged from 35% to 59% of MRH 30, 32, 36, 37 (Table 3) . Cardiovascular medicines were the most commonly prescribed drugs at hospital discharge 31, 36 and were implicated in the largest proportion of MRH, associated with 18.8% to 55.7% of events. [30] [31] [32] [33] 36, 37 Anticoagulants were also a commonly implicated drug class, associated with up to 20% of events 37 . Four studies examined the association between risk factors and MRH, 30, 31, 36, 37 and 3 of these studies performed multivariable analyses to identify independent predictors 30, 31, 36 (Table 4) . More medicines, 30, 36 31 and female sex 31 were independent risk factors for MRH.
DISCUSSION
To our knowledge, this is the first systematic review to describe the epidemiology of MRH in communitydwelling older adults after hospital discharge. We included 8 studies reporting a wide range in incidence of MRH, from 0.4% to 51.2% of participants. We found substantial methodological heterogeneity between studies, including outcome definitions (WHO definition of ADR to no reported definition), population cohort recruited (individuals with polypharmacy to those requiring community nursing care), follow-up period (14-365 days), and data collection methods (using solely medical records to including participant interviews and physical examination). A review of medication-related hospitalizations similarly demonstrated major variations in study characteristics, resulting in a prevalence range of 0.1% to 54% in identified studies 38 . Our review indicates that a lack of consensus on conducting and reporting MRH research continues to hamper a clear understanding of the burden of MRH.
Our results show that a considerable proportion of older adults experience MRH within 30 days after discharge. The 1-month incidence ranges from 167 to 500 events per 1,000 individuals (17-51%). This does not include 1 study that reported an very low incidence of MRH (0.4%) in which only individuals who consulted their GP after discharge were followed. 36 This study excluded MRH that resulted in the use of other health services (e.g., emergency department) or were selfmanaged at home and therefore underreported the magnitude of MRH. Another study found that half of discharged individuals experienced MRH within 2 weeks of discharge 34 . This was a higher incidence than in other studies, and it is likely that it reflects the particularly highrisk cohort of individuals with polypharmacy that were recruited.
Between 35% and 59% of MRH was preventable in the included studies, and this finding builds on a previous systematic review of MRH in the community (not after discharge) in all age groups which reported that 11% to 27.5% as preventable 39 . Given the high risk around hospital discharge of medication discrepancies, 40, 41 poor communication of medication changes and possible adverse effects, 17, 37, 42 and deficiencies in information transfer to primary care, 23 the higher proportion of preventable MRH that we found is not a surprise.
None of the included studies considered the financial costs of MRH to healthcare systems. Reducing preventable MRH after discharge may be an opportunity for financial savings within healthcare systems. An economic analysis of the direct costs from healthcare use attributable to postdischarge MRH in a large, prospective, multicenter study would be a starting point. Data on the costs of MRH that are available are predominantly based on hospitalised patients. 43, 44 Our findings highlight the crucial need for consensus in defining MRH, collecting MRH data, ascribing causality, and reporting findings. There are multiple definitions for ADR and ADE, 3, [5] [6] [7] and they can be contradictory. For example, the WHO definition of ADR stipulates "a response to a medicine which is noxious and unintended, and which occurs at doses normally used in man" 7 (thereby excluding error), whereas another definition includes ADRs related to alternative doses that might have arisen because of error 5 . The common exclusion of MRH due to nonadherence and medical error in ADR studies does not reflect the reality of patient experience 19 or clinical practice 4 . We recommend that future studies identify harm due to nonadherence and medical error alongside ADRs, reporting these separately and collectively under the terminology of MRH. This would align with the WHO's global medication safety initiative 1 . Data collection for MRH studies is more accurate when multiple sources are used 6, 45 . Studies that rely solely on medical chart review are likely to underestimate MRH events 45 ; patient surveys or interviews are a valuable contribution to MRH data 46, 47 and should be routinely used to generate more robust evidence 48 . Only 1 study included a medical examination to look for physical signs of MRH conducted by a physician with clinical pharmacology training. 35 The authors did not report the proportion of MRH identified using this unique approach relative to chart reviews and self-reports, although several participants experiencing statin-induced myopathy and corticosteroid-induced Cushing syndrome were identified who might have been missed without a clinical examination. The value of the examination depends on the education and training of the physician conducting it.
Although there is no gold standard approach for ascribing causality when assessing MRH 49 , combining an algorithmic approach (e.g., Naranjo 50 ) and expert opinion from multiple reviewers is comprehensive and may improve the accuracy of causality judgements 51 . Similar to the Consolidated Health Economic Evaluation Reporting Standards 52 that the International Society for Pharmacoeconomics and Outcomes Research has formulated, we recommend an international, multidisciplinary task force (including academics, clinicians, pharmaceutical industry representatives, regulatory authorities, and patients and caregivers 53 ) to formulate best-practice guidance for investigating and reporting MRH. A Delphi panel, a validated way to achieve expert consensus 54 , could be organized online, requiring minimal financial support.
There is no established timeframe defining the heightened risk of adverse events in the postdischarge period. Five studies (63%) in our review followed participants for 30 days. Although arbitrary, this is consistent with the 'posthospital syndrome' describing a 30-day period of heightened vulnerability from ongoing illness recovery and the physiological stresses of hospitalization, including sleep deprivation, poor nutrition, and deconditioning 20 . One study investigated a 45-day postdischarge period and found the vast majority of MRH occurs within 30 days 32 ; another included 1 year of follow-up and showed that MRH occurred predominantly in the first 3 months 30 . Some MRH manifests over an extended timeframe (e.g., immunosuppression-related sepsis or osteoporotic fracture from extended prednisone use in temporal arteritis). It is likely that these cases of MRH would be missed in a limited follow-up of weeks (or even months), which makes it particularly challenging to propose a specific follow-up period.
Specific medication-related features were associated with greater risk of MRH in more than 1 study. More medicines, a well-established risk factor for MRH in the inpatient setting 55 , was an independent predictor of postdischarge MRH in 2 included studies 30, 36 . Our results also highlighted warfarin as a significant risk factor 30, 36 , although a recently published, included study did not find that anticoagulants were a particularly frequent class of drug implicated in MRH 33 . This could reflect changing prescribing patterns of anticoagulant use from vitamin K antagonists to direct oral anticoagulants and indications that some direct oral anticoagulants have a better safety profile than warfarin 56 . Only 1 study explored the influence of psychosocial factors on the risk of MRH and found that reducing cognition as measured using the MiniMental State Examination was significant 31 . None of the studies investigated the role of low health literacy, which is increasingly recognized as a potentially modifiable determinant of MRH 57 . The influence of other important variables such as frailty, caregiver support, and socioeconomic status has not been explored and could increase our understanding of the pathways underlying MRH.
Our review has several limitations. Although we performed a comprehensive literature search, we could not identify unpublished studies. The heterogeneity of the identified studies precluded a meta-analysis to estimate the incidence of MRH, our primary outcome of interest. Several outcomes of interest, including severity and preventability of MRH, were not reported in all included studies and little further information was added by contact with original investigators. Many studies excluded individuals with dementia and those discharged from psychiatric wards. Given the many medicines that these patients commonly use, it is important that future studies be designed to include such groups.
CONCLUSIONS
MRH is common in older adults after hospital discharge, but methodological inconsistencies between studies limit a clear understanding of its epidemiology. There is a need for further prospective epidemiological research on this topic to identify risk factors and for international consensus on conducting and reporting studies investigating MRH.
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